| Intimation Letter under regulation 30 of SEBI (LODR) Regulations, 2015 |
|
| Sakar submitted 20 dossiers of oncology product registration across regions |
|
| Sakar enters into agreement with 7-partners |
|
| Sakar s oncology (anti-cancer) unit receives EU GMP approval |
|
| Statement of Deviation or Variation under regulation 32 of SEBI(LODR) Regulations, 2015 for the quarter ended on March 31, 2024 |
|
| Investor Conference |
|
| Sakar Interaction with Investor 24th Feb. 2023 |
|
| Statement of Deviation or Variation under regulation 32 of SEBI(LODR) Regulations, 2015 for the quarter ended on September 30, 2023 |
|
| Amendment to MOA AND AOA |
|
| WHO GMP approval received for Oncology Injection (small volume parenteral & lyophilized) unit |
|
| Statement of Deviation or Variation under regulation 32 of SEBI(LODR) Regulations, 2015 for the quarter ended on March 31, 2023 |
|
| Meeting with strategic global team of Ferring Pharmaceutical |
|
| Sakar_Interaction_with_Investor_14th November 2022 |
|
| Updates_on_API_progressed_ in_oncology_segment |
|
| Sakar_Interaction_with_Investor_2nd November 2022 |
|
| Sakar_Interaction_with_Investor_12th October 2022 |
|
| WHO_GMP_Approval |
|
| Sakar Interaction with Investor 8th October 2022 |
|
| Sakar Healthcare enters into an Agreement with Zydus Life Sciences (Cadila Healthcare) to manufacture Oncology |
|
| Sakar Interaction with Investor 29th Sept. and 1st October 2022 |
|
| Auditors Appointment |
|
| Sakar Interaction with Investor Analyst 21st Sept. 2022 |
|
| Sakar Interaction with Investor Analyst 9th Sept. 2022 |
|
| Sakar Interaction with Investor Analyst 2nd and 3rd Sept. 2022 |
|
| MGT-7 2021-22 |
|
| Statement of Deviation or Variation under regulation 32 of SEBI(LODR) Regulations, 2015 for the quarter ended on December 31, 2021 |
|
| Change in Chief financial officer |
|
| Statement of Deviation or Variation under regulation 32 of SEBI(LODR) Regulations, 2015 for the quarter ended on September 30, 2021 |
|
| Re-appointment of directors in 17th AGM |
|
| SAKAR Healthcare – Inauguration of Research Laboratories (R&D, F&D, ADL) |
|
| Statement of Deviation or Variation under regulation 32 of SEBI(LODR) Regulations, 2015 for the quarter ended on June 30, 2021 |
|
| Statement of Deviation or Variation under regulation 32 of SEBI(LODR) Regulations, 2015 for the quarter ended on March 31, 2021 |
|
| FPI Investment in Sakar Healthcare |
|
| Stakeholder Communication |
|
| Amendment in Memorandum of Association |
|
| Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 for Re-appointment of Statutory Auditor |
|
| Business Expansion Oncology |
|
| Statement of Deviation or Variation under regulation 32 of SEBI(LODR) Regulations, 2015 for the quarter ended on March 31,2019 |
|
| Updates – Emerging Bigger |
|
| Non-applicability-of-large-Entities |
|
| Announcement DSIR |
|
| Intimation Letter – submission advertisement publication dated 18th January 2019 |
|
| Intimation Letter under regulation 30 of SEBI (LODR) Regulations, 2015 , dated 17th January 2019 |
|
| Intimation Letter under regulation 30 of SEBI (LODR) Regulations, 2015 for submission of advertisement publication |
|
| Sakar Healthcare Investor Presentation |
|
| Intimation Letter under regulation 30 of SEBI (LODR) Regulations, 2015 , dated 29th November 2018 |
|
| Statement of Deviation or Variation under regulation 32 of SEBI(LODR) Regulations, 2015 |
|
| Intimation Letter under regulation 30 of SEBI (LODR) Regulations, 2015 for change in the Company Secretary |
|
| Intimation Letter under regulation 30 of SEBI (LODR) Regulations, 2015, 19th January 2018 |
|
| Intimation Letter under regulation 30 of SEBI (LODR) Regulations, 2015, 9th june 2017 |
|
| Broker Conference on 29th June, 2022 |
|
| Corrigendum to the Notice of the EGM to be held on 20th March 2018 |
|
